Filing Details
Protalix BioTherapeutics, Inc. (AMEX:PLX) filed a Form 8-K with the Securities and Exchange Commission on November 10, 2026, disclosing a material event.
Protalix BioTherapeutics, Inc. (AMEX:PLX) filed a Form 8-K with the Securities and Exchange Commission on November 10, 2026, disclosing a material event.

At publication ·
Protalix BioTherapeutics, Inc. (AMEX:PLX) · 8k filed
At a glance
Protalix BioTherapeutics, Inc. (AMEX:PLX) filed a Form 8-K with the Securities and Exchange Commission on November 10, 2026, disclosing a material event.
Protalix BioTherapeutics, Inc.'s stock currently trades at $2.86 with a market capitalization of $146.4M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Protalix BioTherapeutics, Inc.'s stock.
All SEC filings for Protalix BioTherapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View PLX Stock Page
Browse all filings on our PLX SEC filings page.
Public companies like Protalix BioTherapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.
Keep reading
earnings ·
sec_filing ·
sec_filing ·
earnings ·
Current market data
AMEX · PLX
$2.90
Down: -$0.16 · -5.23%
Live quote updated